褪去新冠商业化红利反而更强了！药明康德(02359)小分子CDMO单季度收入飙至69.3亿元

智通财经04-27

智通财经APP获悉，4月27日晚间，药明康德(603259.SH/02359)发布了其首季度财报，核心业务增长动能强劲。根据公司最新披露的经营数据，其核心的小分子CDMO(合同研发与生产)业务在2026年第一季度实现收入69.3亿元，单季规模创下历史新高。这一成绩是在完全剔除了新冠商业化项目影响后取得的，标志着公司核心增长引擎已彻底摆脱对特定事件的依赖，全面进入由内生“漏斗”驱动的强劲、可持续增长...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2630325361?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-04-27 17:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2630325361","market":"sh","top_or_hot":-1,"title":"褪去新冠商业化红利反而更强了！药明康德(02359)小分子CDMO单季度收入飙至69.3亿元","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，4月27日晚间，药明康德(603259.SH/02359)发布了其首季度财报，核心业务增长动能强劲。根据公司最新披露的经营数据，其核心的小分子CDMO(合同研发与生产)业务在2026年第一季度实现收入69.3亿元，单季规模创下历史新高。这一成绩是在完全剔除了新冠商业化项目影响后取得的，标志着公司核心增长引擎已彻底摆脱对特定事件的依赖，全面进入由内生“漏斗”驱动的强劲、可持续增长...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1434451.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>褪去新冠商业化红利反而更强了！药明康德(02359)小分子CDMO单季度收入飙至69.3亿元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n褪去新冠商业化红利反而更强了！药明康德(02359)小分子CDMO单季度收入飙至69.3亿元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-27 17:17 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1434451.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，4月27日晚间，药明康德(603259.SH/02359)发布了其首季度财报，核心业务增长动能强劲。根据公司最新披露的经营数据，其核心的小分子CDMO(合同研发与生产)业务在2026年第一季度实现收入69.3亿元，单季规模创下历史新高。这一成绩是在完全剔除了新冠商业化项目影响后取得的，标志着公司核心增长引擎已彻底摆脱对特定事件的依赖，全面进入由内生“漏斗”驱动的强劲、可持续增长...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1434451.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2488822045.USD","symbol_name":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1434451.html","article_id":"2630325361","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2630325361","pubTimestamp":1777281471,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，4月27日晚间，药明康德发布了其首季度财报，核心业务增长动能强劲。此次小分子CDMO业务单季收入逼近70亿元大关，具有非凡的里程碑意义。数据显示，截至一季度末，药明康德小分子CDMO管线总数已达3550个。此次小分子CDMO业务在“后新冠时代”创下收入新高，是药明康德从“事件驱动”增长全面转向“平台驱动”持续高增长的有力证明，也为其在全球医药产业链中的核心枢纽地位再添坚实注脚。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"603259":"药明康德","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0456842615.SGD":"JPMorgan Funds - Emerging Markets Equity A (acc) SGD","CDMO":"Avid Bioservices, Inc.","LU2045819591.USD":"Natixis WCM Global Emerging Markets Equity R/A USD","LU0052750758.USD":"富兰克林中国基金A Acc","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","LU0348766576.USD":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC","LU2125910500.SGD":"Natixis WCM Global Emerging Markets Equity H-R/A SGD","BK1141":"生命科学工具和服务","02359":"药明康德","BK1576":"医药外包概念","LU1979443071.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"AD\" (USDHDG) INC","LU0348767384.USD":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","LU1046422090.SGD":"Fidelity Pacific A-SGD","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","BK4139":"生物科技","LU1934453819.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"A\" (USD) ACC","BK1583":"高瓴概念","BK0216":"研究试验","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1808992512.USD":"AB ALL CHINA EQUITY PORTFOLIO \"A\" (USD) ACC","LU1997245177.USD":"安联神洲A股基金"},"translate_title":"Fade the commercialization dividend of COVID-19, but it is stronger! WuXi AppTec (02359) small molecule CDMO single-quarter revenue soared to 6.93 billion yuan","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603259":1.5,"02359":1.5,"CDMO":1.5},"content_text":"智通财经APP获悉，4月27日晚间，药明康德(603259.SH/02359)发布了其首季度财报，核心业务增长动能强劲。根据公司最新披露的经营数据，其核心的小分子CDMO(合同研发与生产)业务在2026年第一季度实现收入69.3亿元，单季规模创下历史新高。这一成绩是在完全剔除了新冠商业化项目影响后取得的，标志着公司核心增长引擎已彻底摆脱对特定事件的依赖，全面进入由内生“漏斗”驱动的强劲、可持续增长阶段。此次小分子CDMO业务单季收入逼近70亿元大关，具有非凡的里程碑意义。回溯2022至2023年间，新冠相关的巨额商业化订单曾为公司带来显著的阶段性收入。如今，在无任何新冠订单扰动的情况下，小分子CDMO单季收入依然能够强势超越彼时的峰值。这充分证明了药明康德独创的CRDMO商业模式具备极其强大的自我造血与持续增长能力，其增长质量更高、抗风险韧性更强。业绩突破的背后，是公司小分子管线的持续高质量扩张与转化。数据显示，截至一季度末，药明康德小分子CDMO管线总数已达3550个。其中，处于商业化生产阶段的项目增至89个，临床III期项目达94个。高价值后期项目的不断增多，直接推动了收入体量与盈利质量的同步跃升。公司长期坚持的“跟随分子”战略，确保了早期项目能够高效向后端临床及商业化阶段转化，形成了源源不断的收入源泉。强大的业绩兑现能力，同样离不开全球领先的产能支撑。截至2025年底，药明康德小分子原料药合成反应釜总体积已超过400万升，构筑了深厚的产能壁垒。同时，其位于常州、泰兴及金山等地的原料药基地均以高质量标准通过了全球监管机构的检查，确保了稳定、可靠的商业化供应能力。此次小分子CDMO业务在“后新冠时代”创下收入新高，是药明康德从“事件驱动”增长全面转向“平台驱动”持续高增长的有力证明，也为其在全球医药产业链中的核心枢纽地位再添坚实注脚。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2630325361","isCrawlerRequest":true}